PersoMed-I is phase II, randomised international trial of personalised therapy, including sonidegib, for adolescents and young adults with SHH pathway activated medulloblastoma.
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown
NSW, 1450
Australia
Email: persomed.study@sydney.edu.au
Sonidegib and radiotherapy
DEVELOPMENT OF RANDOMIZED TRIALS IN ADULTS WITH MEDULLOBLASTOMA—THE EXAMPLE OF EORTC 1634-BTG/NOA-23.
Peter Hau, Didier Frappaz, Elizabeth Hovey, Martin G. McCabe, Kristian W. Pajtler, Benedikt Wiestler, Clemens Seidel, Stephanie E. Combs, Linda Dirven, Martin Klein, Antoinette Anazodo, Elke Hattingen, Silvia Hofer, Stefan M. Pfister, Claus Zimmer, Rolf-Dieter Kortmann, Marie-Pierre Sunyach, Ronan Tanguy, Rachel Effeney, Andreas von Deimling, Felix Sahm, Stefan Rutkowski, Anna S. Berghoff, Enrico Franceschi, Estela Pineda, Dagmar Beier, Ellen Peeters, Thierry Gorlia, Maureen Vanlancker, Jacoline E. C. Bromberg, Julien Gautier, David S. Ziegler, Matthias Preusser, Wolfgang Wick and Michael Weller. Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23.
Cancers. 13(14), 3451 (2021).
Published online 9 July 2021. Article available on https://doi.org/10.3390/cancers13143451
0 recruited patients
8 target
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown
NSW, 1450
Australia
